Co-Authors
This is a "connection" page, showing publications co-authored by VICENTE VALERO and MEDIGET TESHOME.
Connection Strength
0.869
-
ASO Visual Abstract: Residual Nodal Burden After Neoadjuvant Chemotherapy in cN1 Breast Cancer Patients with Positive Nodes on Targeted Axillary Dissection. Ann Surg Oncol. 2024 Aug 01.
Score: 0.248
-
Residual Nodal Burden After Neoadjuvant Chemotherapy in cN1 Breast Cancer Patients with Positive Nodes at Targeted Axillary Dissection. Ann Surg Oncol. 2024 Jul 23.
Score: 0.247
-
Low Rates of Local-Regional Recurrence Among Inflammatory Breast Cancer Patients After Contemporary Trimodal Therapy. Ann Surg Oncol. 2023 Oct; 30(10):6232-6240.
Score: 0.058
-
Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs. 2023 Jun; 41(3):391-401.
Score: 0.057
-
Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer. Ann Surg Oncol. 2021 Dec; 28(13):8610-8621.
Score: 0.050
-
The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer. Ann Surg Oncol. 2021 Aug; 28(8):4265-4274.
Score: 0.048
-
Patient Selection for Clinical Trials Eliminating Surgery for HER2-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy. Ann Surg Oncol. 2019 Oct; 26(10):3071-3079.
Score: 0.044
-
A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Ann Surg. 2018 05; 267(5):946-951.
Score: 0.040
-
International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. J Cancer. 2018; 9(8):1437-1447.
Score: 0.040
-
Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. JAMA Surg. 2017 07 01; 152(7):665-670.
Score: 0.038